Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.

Inclusion Criteria: * Patients with diabetes mellitus type 1 or type 2 complicated by PDR * Male or female over 18 years * HbA1c \<11.6% at study entry * Systolic blood pressure \<160 mmHg and diastolic blood pressure \<105 mmHg at study entry * Backgrounds clear eye, pupil dilation and patient cooperation sufficient to allow examination or fundus photographs of good quality Exclusion Criteria: * Hypersensitivity to aflibercept or to any of the excipients * History of retinal laser (macular or panretinal photocoagulation), of intravitreal injections, of vitrectomy in the eye studied * PDR associated with tractional retinal detachment in the eye studied * PDR associated with fibrovascular proliferation in the eye studied * Florid diabetic retinopathy * Eye infection or periocular active or suspected * Unbalanced glaucoma in the eye studied * Other eye disease in the eye studied * Patients with significant medical problems that may interfere with the evaluation of the safety or efficacy of the treatment studied